Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study.
- Lee, Ki Hyeong; Ahn, Myung-Ju; Han, Ji-Youn; Kim, Sang-We; Cho, Eun Kyung; Lee, Yun-Gyoo; Kim, Dong-Wan; Kim, Joo-Hang; Lee, Jong-Seok; Lee, Gyeong-Won; Shim, Byoung Yong; Kim, Jin-Soo; Chun, Sang Hoon; Lee, Sung Sook; Min, Young Joo; Shin, Sang Won; Hong, Min Hee; Sun, Jong-Mu; Byun, Hae Mi; Cho, Byoung Chul
- Issue Date
- LIPPINCOTT WILLIAMS & WILKINS
- JOURNAL OF CLINICAL ONCOLOGY, v.38, no.15
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Files in This Item
- There are no files associated with this item.
- Appears in
- College of Medicine > Department of Medicine > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.